Literature DB >> 8450219

Culture of human monocytes with granulocyte-macrophage colony-stimulating factor results in enhancement of IFN-gamma receptors but suppression of IFN-gamma-induced expression of the gene IP-10.

D S Finbloom1, A C Larner, Y Nakagawa, D L Hoover.   

Abstract

The initiation and promulgation of chronic inflammation are controlled in part by the various pro-inflammatory and anti-inflammatory cytokines present at the site of injury. IFN-gamma and granulocyte-macrophage CSF (GM-CSF) are two cytokines that can contribute to the inflammatory state and possess both pro- and anti-inflammatory properties. However, the characterization of the interaction between GM-CSF-cultured monocytes and IFN-gamma is poorly documented. In this report we show that culture of human peripheral blood monocytes for up to 6 days in the presence of GM-CSF results in an eightfold increase in the level of IFN-gamma R expression, as determined by radioligand binding. The IFN-gamma R on these cells maintains a specificity typical of that observed in fresh monocytes. Only IFN-gamma, not IFN-alpha or -beta, blocks the binding of IFN-gamma to its receptor, and anti-IFN-gamma R antibodies block at least 80% of binding of IFN-gamma to these cultured cells. However, in spite of increased receptor expression, GM-CSF-cultured monocytes have a diminished response to IFN-gamma, as measured by the induction of the gene for IP-10 (a member of the platelet factor-4/IL-8 family). On the other hand, IFN-gamma-induced activation of the DNA-binding protein FcRF gamma is maintained in GM-CSF-cultured monocytes. Therefore, suppression of IFN-gamma-mediated IP-10 induction is not the result of a global abrogation of signal transduction across the IFN-gamma R but a more selective inhibition that appears to occur downstream of the receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450219

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways.

Authors:  A M O'Farrell; Y Liu; K W Moore; A L Mui
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

2.  Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice.

Authors:  Hui Zhang; Gary G Meadows
Journal:  Cancer Immunol Immunother       Date:  2010-03-13       Impact factor: 6.968

3.  Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria.

Authors:  J Riopel; M Tam; K Mohan; M W Marino; M M Stevenson
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells.

Authors:  Gautam Damera; Hengjiang Zhao; Miao Wang; Michael Smith; Christopher Kirby; William F Jester; John A Lawson; Reynold A Panettieri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-06       Impact factor: 5.464

5.  In vitro activation of a transcription factor by gamma interferon requires a membrane-associated tyrosine kinase and is mimicked by vanadate.

Authors:  K Igarashi; M David; A C Larner; D S Finbloom
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

6.  Dexamethasone up-regulates granulocyte-macrophage colony-stimulating factor receptor expression on human monocytes.

Authors:  C M Hawrylowicz; L Guida; E Paleolog
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

7.  Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis.

Authors:  H W Murray; J S Cervia; J Hariprashad; A P Taylor; M Y Stoeckle; H Hockman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

8.  Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide.

Authors:  Prati Pal Singh; Priya Singal
Journal:  J Neuroimmune Pharmacol       Date:  2007-10-10       Impact factor: 7.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.